Laboratory of Cell Death and Inflammation
The most effective way to treat cancer is to kill cancer cells. Our research focuses on understanding the unexpected consequences of cell death. In particular, we investigate what happens when cell death pathways fail or become dysregulated, and how this can trigger alternative outcomes such as tumour development and activation of immune responses.
Using multidisciplinary experimental approaches, we investigate the molecular, cellular, and organismal consequences of failed or abnormal cell death.
Ultimately, we aim to translate these discoveries into improved therapies for a wide range of human diseases.
Lab News
October 2026
Marlene will present her PhD project at the Cell Press Symposium “Taking programmed cell death from mechanisms to interventions” in Hangzhou, China.
Laura joins the lab for her Master’s thesis. She will understand the link between apoptotic signalling and onset of senescence. Welcome, Laura!
September 2026
Nadine will present her work about sub-lethal apoptotic signalling in B cell lymphomas at the Non-Lethal Roles of Cell Death Proteins conference in Madrid. Joel will also present the lab’s work on mitochondrial cell death-triggered inflammation.
July 2026
Leonardo has successfully defended his Master’s thesis, with distinction. Congratulations, Leo!
June 2026
Nadine’s method for BH3 profiling in primary mouse B cells has been published - you can read it here.
March 2026
Petra joins the lab for her Master’s thesis and will investigate environmental triggers of sub-lethal cell death. Welcome, Petra!
Janina has also joined the lab for her Master’s thesis. She will use cutting-edge proteomics approaches to understand how mitochondrial cell death is inflammatory. Welcome, Janina!
February 2026
Lisa joins the lab for her Master’s thesis. She will work on sub-lethal cell death signalling in B cell lymphomas. Welcome, Lisa!
Oriol also joins the lab for his Bachelor’s thesis from the University of Lleida. He aims to understand more about drug resistance in B cell lymphomas. Welcome, Oriol!